Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

You are right on that front. After June ended I looked for them to release data and pictures in December as promised by the CEO. What we got was a press release stating the following"

"RXI-109 continues to work in patients with hypertrophic scarring" and that's all we got.

That leads me to believe that the scar trial is a bust. which makes sense after they had no money for the scar trials and continued to diversify into other products like samcyprone and cosmecueticals.

Here is the press release from December of 2016 and what was stated, instead of data and photos that was promised:

http://investors.rxipharma.com/news-releases/news-release-details/rxi-pharmaceuticals-provides-year-end-update-its-business

"Clinical trial RXI-109-1402: Confirmed efficacy and safety of RXI-109 to reduce the formation of hypertrophic scars after scar revision surgery."

and

"In fact, new data in the RXI-109 dermal trial confirm and extend the 3-month data previously reported for subjects treated with 5 mg/cm and indicate a positive effect of RXI-109 out to 6 months after the last dose."

But no data? okay? That is why I sold back in December of 2016, put all new money into Conatus pharmaceuticals (CNAT) bought 10,000 shares at $1.90 it is now at $6.50 per share. IMO that management team made a deal with novartis and that team cares about its shareholders.